The total market of antidepressants is over 10 billion yuan! Top 5 continuous development

Among the first batch of 12 products released on December 29, 2017 through the consistency evaluation of quality and efficacy of generic drugs, the selective 5-hydroxytryptamine reuptake inhibitor paroxetine of Huahai Pharmaceutical Co., Ltd is on the list The drug is a first-line drug for the treatment of various types of depression, and also one of the top five drugs for the treatment of depression in public hospitals in key cities in China Overall overview the fourth largest chronic disease according to the research report released by the World Health Organization: more than 350 million people in the world suffer from different degrees of depression, and less than half of the people in western countries can get the treatment needed, while in developing countries and regions, the proportion is even less than 10% Experts from the Psychiatric Society of the Chinese Medical Association pointed out that the prevalence of depression in China is similar to that in foreign countries Depression is a kind of central neurotransmitter conduction dysfunction induced by genetic, psychological and neuroendocrine factors It belongs to non psychopathic functional disorder Personality and social psychological factors are the main pathogenic factors With the gradual expansion of depression, this disease has become the fourth major chronic disease after cancer, stroke and COPD The total market reached 10 billion yuan in the national health insurance catalogue issued in 2017 The clinical use of psychostimulants for antidepressants includes three categories: non selective monoamine reuptake inhibitors, selective serotonin reuptake inhibitors, and other antidepressants, totaling 21 drugs At present, there are more than 55 million depression patients in China, and about 1 million suicides are caused by depression every year Under the influence of physiological, social factors and chronic diseases, the prevalence of depression in women is twice as high as that in men, and it is more common in women It is predicted that depression will leap to the second largest disease by 2020 At present, the structure of clinical antidepressants in China is gradually improved, which is mainly composed of six categories: selective 5-HT reuptake inhibitors (SSRI), selective 5-HT and NE reuptake inhibitors (SNRI), NE and specific 5-HT antidepressants (Nassa), 5-HT receptor antagonists and reuptake inhibitors (saris), selective 5-HTIA receptor agonists and other drugs According to the data of minenet from January to March 2017, there are 26 kinds of antidepressants in public hospitals in key cities in China The amount of antidepressants used in 16 sample hospitals in China is expected to reach 1.295 billion yuan, an increase of 11.83% over the previous year The top 5 drugs are paroxetine, escitalopram, sertraline, venlafaxine and duloxetine It is estimated that in 2017, the amount of antidepressants used in public hospitals in key cities in China was nearly 1 billion yuan, accounting for 70% of the total market It is predicted that the total market size of antidepressants in China will exceed 10 billion yuan Paroxetine is a selective 5-HT reuptake inhibitor, which is a new type of antidepressant with dual effects In 1991, paroxetine was successfully developed by GlaxoSmithKline In December 1992, paroxetine was approved by FDA and listed as Paxil It has been listed in nearly 100 countries and regions for clinical use The global market for the drug exceeded $3 billion in 2003 After the expiration of the patent, Paxil's global sales volume was 316 million US dollars in 2016 due to the impact of generic drug listing Paroxetine entered the Chinese market earlier On November 7, 1995, the former Ministry of Health approved the production of paroxetine tablets from Tianjin Shike of China and the United States as four new drugs, with the trade name of "celete" With the rapid launch of antidepressant market, paroxetine made in China has also been well developed CFDA approved the registration of paroxetine tablets of Zhejiang Huahai Pharmaceutical Co., Ltd in 2003, then approved paroxetine tablets of Zhejiang Jianfeng Pharmaceutical Co., Ltd and paroxetine tablets of Beijing Wansheng Pharmaceutical Co., Ltd in 2013 At present, there are only 3 domestic paroxetine drugs in the domestic market Sales of paroxetine tablets of GSK have been in a downward trend in recent three years In the first three quarters of 2017, the total sales volume of Huahai pharmaceutical paroxetine was almost the same as that of the original research drug, with a trend of replacing the original research drug According to minenet data, in 2016, the amount of paroxetine used in public hospitals in key cities in China reached 146 million yuan, an increase of 6.6% over the previous year China and the United States accounted for 50.99% of Celeste, 37.42% of huayai, 9.73% of Zhejiang peak, and 1.82% of Beijing Wansheng pharmaceutical According to the data forecast of the first three quarters of 2017, the amount of paroxetine used in 16 sample hospitals in China reached 153 million yuan in 2017, an increase of 4.80% over the previous year, and the amount of paroxetine used in China reached 1 billion yuan in the whole year Escitalopram: it is used for severe depression and has a strong future market Escitalopram is jointly developed and listed by Danish Lingbei pharmaceutical and American forest laboratory Its trade name is lexapro / cipralex It was approved by FDA to be listed in the United States in 2002 In 2006, escitalopram, located in Lingbei, Denmark, entered the market of our country, with the commodity name of "lysop" In 2008, China approved the products of Shandong Jingwei Pharmaceutical Co., Ltd and Sichuan Kelun Pharmaceutical Co., Ltd to be listed on the market In recent years, Zhejiang Jinhua Kangenbei biopharmaceutical Co., Ltd., Hunan Dongting Pharmaceutical Co., Ltd and West Point Pharmaceutical Co., Ltd of Jilin Province were approved for listing At present, there are 5 domestic products of escitalopram tablets on the market Escitalopram is the active isomer of citalopram It is one of the first antidepressant drugs for the treatment of major depressive disorder, so it is favored by doctors and patients It is predicted that the amount of escitalopram used in 16 sample hospitals in China in 2017 will reach 280 million yuan, an increase of 17.65% over the previous year Compared with other antidepressants, the drug has a significant effect on severe depression and a better safety Therefore, although the product was launched late, its growth trend is obvious Sertraline: Pfizer Zoloft accounts for eight components Sertraline was developed by Pfizer In 1990, sertraline was first listed in the UK under the trade name Zoloft It was approved by FDA in December 1991 and has been listed in more than 100 countries and regions Sertraline has been the largest prescription antidepressant brand in the United States for many years Research shows that the drug has a good effect on social anxiety, and it has become the first-line treatment At the same time, the drug is also used in the treatment of premenstrual dysphoria and adults, children obsessive-compulsive disorder and traumatic stress disorder At the end of last century, Pfizer has introduced sertraline into the Chinese market, with the commodity name of "Zoloft" At present, CFDA has approved 39 domestic production approvals It is predicted that in 2017, the amount of sertraline used in 16 sample hospitals in China will reach 180 million yuan, an increase of 12.50% over the previous year, ranking the second in the antidepressant market Pfizer's Zuo Luofu accounts for 80%, Zhejiang Jingxin for 12.87%, Chengdu lile for 2.52% and Zhejiang Huahai for 1.2% Venlafaxine: venlafaxine is the best 5-hydroxytryptamine-noradrenaline reuptake inhibitor in clinical use The product was developed by Wyeth It was approved by FDA in December 1993 It was first listed in the United States in April 1994, with the trade name of efexor Venlafaxine belongs to a new class of phenylethylamine derivatives, which is suitable for all kinds of depression, anxiety depression and generalized anxiety disorder It also has a good effect on depression with both psychomotor retardation and agitation behavior characteristics In November 1999, venlafaxine of Dutch AHP pharmaceutical obtained administrative protection in China, and then fexor, a sustained-release capsule of Wyeth ayerst in the United States, was registered and listed in China The development of venlafaxine by Chongqing pharmaceutical industry research institute and Chengdu Kanghong Pharmaceutical Group was successful In October 1998, CFDA approved Chengdu Hongda pharmaceutical and Chengdu Kanghong pharmaceutical to produce venlafaxine raw materials and capsules, with the commodity name of "bolexin"
As of October 2016, CFDA has approved 19 enterprises to produce venlafaxine APIs; Chengdu Kanghong Pharmaceutical Co., Ltd., Guizhou shengjitang Pharmaceutical Co., Ltd., Beijing Wansheng Pharmaceutical Co., Ltd., Chengdu Beite Pharmaceutical Co., Ltd., Chengdu Hengrui Pharmaceutical Co., Ltd., Chengdu Southwest Pharmaceutical Co., Ltd., Suzhou No.4 Pharmaceutical Co., Ltd., Changzhou No.4 Pharmaceutical Co., Ltd., Shandong Xinqi Pharmaceutical Co., Ltd., Sichuan Hezheng Pharmaceutical Co., Ltd., Shanghai Xinya Pharmaceutical Co., Ltd and Lepu Pharmaceutical Co., Ltd And other 14 enterprises produce venlafaxine preparation It is predicted that in 2017, the amount of venlafaxine used in 16 sample hospitals in China will reach 164 million yuan, an increase of 7.19% over the previous year Duloxetine: the market share has steadily increased Duloxetine is the main product of Lilly It was approved by FDA in 2004, and approved to enter the Chinese market in 2006 Its trade name is xinbaida It is a new dual transmitter antidepressant At present, in addition to the imported products of Lilly, there are also the products of Shanghai Shangyao Zhongxi Pharmaceutical Co., Ltd., Jiangsu Enhua Pharmaceutical Co., Ltd and Shanghai Wanxiang Pharmaceutical Co., Ltd Duloxetine is Lilly's top selling drug By the end of November 2017, CFDA had newly approved Zhejiang Huahai Pharmaceutical Co., Ltd and Chongqing shenghuaxi Pharmaceutical Co., Ltd to produce duloxetine API It is predicted that the amount of duloxetine used in 16 sample hospitals in China in 2017 will reach 125 million yuan, an increase of 16.82% compared with the previous year The growth trend is obvious, the market share of antidepressants has been steadily increased in recent years, and the market prospect is promising Antidepressant traditional Chinese medicine: the total domestic market is more than 1 billion Chinese medicine is also the "play" on the antidepressant stage The antidepressant Chinese patent medicines on the market in China include Jieyu pill, Puyu capsule, Anle tablet, shushenling capsule, Ningxin Anshen capsule, Naolejing oral liquid, Jieyu Anshen granule and Zhenling Jieyu capsule The total sales volume of antidepressants in the domestic market is more than 1 billion yuan In addition, there are also "foreign traditional Chinese medicine", such as the St John's wort extract tablet / capsule of Dr Weimar Schumpeter pharmaceutical factory in Germany Conclusion from the perspective of domestic drug market, the overall scale of antidepressant drug market is still small, but with the continuous progress of society, people's living standards continue to improve, doctors gradually improve the recognition rate of depression, people's concept of medical treatment changes, and the quality of spiritual life is also more and more important It can be predicted that the potential of antidepressant market in the future is unlimited.